Related Experiment Video
Updated: Jun 28, 2026

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators
1Molecular Medicine and Medical Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.
Abstract:
Expression of the epithelial cell adhesion molecule EpCAM is upregulated in a variety of carcinomas. This antigen is therefore explored in tumour diagnosis, and clinical trials have been initiated to examine EpCAM-based therapies. Notably, the possible intracellular effects and signalling pathways triggered by EpCAM-specific antibodies are unknown. Here, we show treatment of the mouse lung carcinoma cell line A2C12, of the human lung carcinoma cell line A549 and the human colorectal cell line Caco-2 with the monoclonal EpCAM antibody G8.8 to cause dose dependently an increase in cell proliferation, as determined by the MTS and the 5'-bromo-2'-deoxyuridine (BrdU) labelling assay. Furthermore, a genome-wide approach identified networks of regulated genes, most notably cell cycle regulators, upon treatment with an EpCAM-specific antibody. Indeed, changes in the expression of cell cycle regulators agreed well with the BrdU labelling data, and an analysis of differentially expressed genes revealed the processes with the strongest over-representation of modulated genes, for example, cell cycle, cell death, cellular growth and proliferation, and cancer. These data suggest that EpCAM is involved in signal transduction triggering several intracellular signalling pathways. Knowing EpCAM signalling pathways might lead to a reassessment of EpCAM-based therapies.
Insights
EpCAM antibodies increase cancer cell proliferation by affecting cell cycle regulators. Understanding these EpCAM signaling pathways could impact future cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Epithelial cell adhesion molecule (EpCAM) expression is elevated in various carcinomas.
- EpCAM is a target for tumor diagnosis and EpCAM-based therapies.
- Intracellular effects and signaling pathways of EpCAM-specific antibodies are largely unknown.
Purpose of the Study:
- To investigate the intracellular effects of EpCAM-specific antibodies.
- To identify signaling pathways triggered by EpCAM engagement.
- To explore the impact of EpCAM antibodies on cancer cell proliferation and gene expression.
Main Methods:
- Treatment of carcinoma cell lines (A2C12, A549, Caco-2) with a monoclonal EpCAM antibody (G8.8).
- Assessment of cell proliferation using MTS and 5'-bromo-2'-deoxyuridine (BrdU) labeling assays.
- Genome-wide gene expression analysis to identify regulated networks and pathways.
Main Results:
- EpCAM antibody treatment dose-dependently increased proliferation in tested carcinoma cell lines.
- Genome-wide analysis revealed regulation of cell cycle regulators and other key pathways.
- Gene expression changes correlated with BrdU labeling data, highlighting impacts on cell cycle, death, growth, and proliferation.
Conclusions:
- EpCAM is involved in signal transduction, activating intracellular signaling pathways.
- EpCAM antibody-induced signaling affects critical cellular processes including proliferation and cell cycle.
- Elucidating EpCAM signaling pathways may necessitate a re-evaluation of current EpCAM-based therapeutic strategies.
Related Concept Videos
Positive Regulator Molecules
Positive Regulator Molecules
Inhibition of Cdk Activity
Negative Regulator Molecules
Mitogens and the Cell Cycle
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...

